Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight
Revolution Medicines Inc (NASDAQ:RVMD) leads in precision oncology with a $1.5 billion deficit, strategic partnerships, and a robust pipeline, facing market competition and regulatory challenges.
Tezspire succeeds in Phase III nasal polyps trial
AstraZeneca and Amgen's Tezspire met co-primary endpoints in a Phase III trial for chronic rhinosinusitis with nasal polyps, showing significant reduction in nasal polyps and congestion. Tezspire, a TSLP inhibiting monoclonal antibody, also received FDA breakthrough therapy designation for COPD. The therapy competes with Sanofi and Regeneron's Dupixent, which generated €10.7bn in sales in 2022. Both Tezspire and Dupixent are projected to see increased sales by 2030.
Patient Recruitment for Rare Disease Trials Summit
The Patient Recruitment for Rare Disease Trials Summit tackles challenges like geographical dispersion and low awareness by exploring innovative strategies to efficiently identify and engage eligible participants, featuring actionable insights, knowledge on patient feedback integration, best practices for data sharing, and fair patient reimbursement discussions.
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
CervoMed Inc. wins Prix Galien USA 2024 Best Startup award for developing potential treatment for Dementia with Lewy bodies (DLB), a condition affecting over 1.4 million patients in the U.S. and EU. The company's drug, neflamapimod, is in Phase 2b clinical trial, with topline results expected in December 2024.
Expert Comments on the Risks and Benefits of Tirzepatide Following the Death of Susan McGowan
Experts discuss tirzepatide's safety and benefits after a UK death linked to the drug, highlighting the need for high-quality trials and the importance of the 'yellow card scheme' for reporting side effects.
ALX ONCOLOGY HOLDINGS INC SEC 10-Q Report
ALX Oncology's Q3 2023 Form 10-Q reports financial improvements, ongoing evorpacept trials, strategic initiatives, and challenges in advancing its CD47 checkpoint pathway therapies.
Among 2024's modest M&A action, cancer, immunology and neuroscience deals trickle in
In 2024, smaller deals have dominated pharma M&A, with no single deal surpassing $5 billion. Despite this, M&A remains crucial for refilling pipelines and supporting smaller biotechs. Notable deals include Vertex's $4.9 billion acquisition of Alpine Immune Sciences, Eli Lilly's $3.2 billion acquisition of Morphic, and Gilead's $4.3 billion purchase of CymaBay. Oncology and neuroscience have seen significant activity, with Novartis and AstraZeneca leading in oncology, and Bristol Myers Squibb and Lundbeck in neuroscience.
EMA approves Sanofi/Regeneron's Dupixent for young EoE patients
EMA approves Sanofi/Regeneron’s Dupixent for EoE in children aged 1-11, weighing at least 15kg, based on EoE KIDS trial results. Dupixent is the first approved treatment for these young patients, with efficacy and safety consistent with its profile in adolescents and adults.
Sanofi/Regeneron's Dupixent approved by EC for younger eosinophilic oesophagitis patients
Sanofi and Regeneron's Dupixent approved by EC for EoE in children aged 1-11 years, weighing at least 15kg, not controlled by conventional therapy. Dupixent showed 68% histological remission vs 3% placebo in phase 3 EoE KIDS trial, with sustained results up to one year.
© Copyright 2025. All Rights Reserved by MedPath